Print this page
-
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma.
Protocol: 011909Principal Investigator:
- Mansi Shah MD (Rutgers University)
Applicable Disease Sites: Multiple Myeloma -
Phase II study to assess the efficacy of combined tafasitamab and rituximab in front-line treatment of post-transplant lymphoproliferative disorder
Protocol: 012306Principal Investigator:
- Joanna Rhodes MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 2 Study of Mosunetuzumab with Lenalidomide Augmentation as First-Line Therapy for Follicular and Marginal Zone Lymphoma.
Protocol: 012319Principal Investigator:
- Matthew Matasar (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma.
Protocol: 012402Principal Investigator:
- Mansi Shah MD (Rutgers University)
Applicable Disease Sites: Multiple Myeloma -
A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia.
Protocol: 112402Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Leukemia, other -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma